There has not been as much information about COVID-19 and oral cladribine as has occurred with anti-CD20. In view of the launch of ChariotMS by ProfK. This case report is welcome news in that both people who developed COVID were not hosptialised and recovered. They were relatively young and may be expected to recover but the fact that they had COVID shortly after treatment when the depleting effects would be maximal bodes well and the fact that the person could make an antibody response when B cells should be depleted is encouraging
Preziosa P, Rocca MA, Nozzolillo A, Moiola L, Filippi M. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. J Neurol. 2020 Nov 20. doi: 10.1007/s00415-020-10309-4.
This talks about two people out of 56 in the practice on cladribine. One person appeared to be infected in the first week after the first set of tablets. They were not SARS-CoV-2 PCR tested and they didn’t make an antibody response when tested 4 months later. The second person was also not tested for virus but positive for antibody 2 months later
The second RRMS patient is a 40-year-old female with a disease duration of 13.4 years, moderate disability (EDSS=3.5), and no comorbidities. She started cladribine on February 13th 2020 and underwent the second week of the first treatment course from March 5th 2020. On March 30th, she developed fever (<37.8°), anosmia (lack of smell), ageusia (loss of taste), cough, fatigue, and bone/joint pain. Serology for SARS-CoV-2 performed in May 2020 was positive. Blood examinations both before and after COVID-19 disease were normal.